l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review
Primer Autor |
Farias, Jorge G.
|
Co-autores |
Tosta Perez, Maria
Herrera Belen, Lisandra
Letelier, Pablo
Calle, Yolanda
Pessoa, Adalberto
|
Título |
l-Asparaginase as the gold standard in the treatment of acute lymphoblastic leukemia: a comprehensive review
|
Editorial |
HUMANA PRESS INC
|
Revista |
MEDICAL ONCOLOGY
|
Lenguaje |
en
|
Resumen |
l-Asparaginase is an antileukemic drug long approved for clinical use to treat childhood acute lymphoblastic leukemia, the most common cancer in this population worldwide. However, the efficacy and its use as a drug have been subject to debate due to the variety of adverse effects that patients treated with it present, as well as the prompt elimination in plasma, the need for multiple administrations, and high rates of allergic reactions. For this reason, the search for new, less immunogenic variants has long been the subject of study. This review presents the main aspects of the l-asparaginase enzyme from a structural, pharmacological, and clinical point of view, from the perspective of its use in chemotherapy protocols in conjunction with other drugs in the different treatment phases.
|
Fecha Publicación |
2023
|
Tipo de Recurso |
artículo de revisión
|
doi |
10.1007/s12032-023-02014-9
|
Formato Recurso |
PDF
|
Palabras Claves |
Acute lymphoblastic leukemia
Asparaginase
Antineoplastic agent
Immunogenicity
Hypersensitivity
|
Ubicación del archivo | |
Categoría OCDE |
Oncología
|
Materias |
Leucemia linfoblástica aguda
asparaginasa
Agente antineoplásico
Inmunogenicidad
Hipersensibilidad
|
Identificador del recurso (Mandatado-único) |
artículo de revisión
|
Versión del recurso (Recomendado-único) |
versión publicada
|
Derechos de acceso |
restringido
|
Access Rights |
restringido
|
Id de Web of Science |
WOS:000969750300002
|
ISSN |
1357-0560
|
Tipo de ruta |
verde / dorado
|
Categoría WOS |
Oncología
|
Referencia del Financiador (Mandatado si es aplicable-repetible) |
ANID 21210710
CNPQ 301832/2017-0
|